Search LAB
STANDARD BIOTOOLS INC.
Nasdaq · CIK 1162194
Last close0.74
Daily change+0.01 (1.37%)
10 Years gain-90.75%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LAB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
23.5Momentum
100.0Acceleration
100.0Confidence
90.0Annual Revenue17
Quarterly Revenue68
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth1.8 / 25
Quality5.3 / 25
Capital Efficiency1.1 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.4 / 5
Signals
Operating leverageOperating margin improved by 13.7052 percentage points.
ROIC expansionROIC improved by 113.2266 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM-25.17%OK
Revenue CAGR 3Y-4.49%OK
Gross Margin50.82%OK
Operating Margin-116.9%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-37.13%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.35%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $85.33M | $42.54M | -$110.25M | -$74.34M | -$82.65M | 49.86% | -129.2% | -96.85% | -41.89% | 381.62M |
| 2025 FY Dec 31, 2024 | $91.01M | $44.88M | -$127.49M | -$143.45M | -$151.81M | 49.32% | -140.08% | -166.81% | n/a | 353.25M |
| 2025 FY Dec 31, 2023 | $106.34M | $50.45M | -$76.60M | -$43.29M | -$46.12M | 47.44% | -72.03% | -43.37% | n/a | 79.16M |
| 2024 FY Dec 31, 2022 | $97.95M | $37.05M | -$116.21M | -$89.37M | -$93.20M | 37.83% | -118.64% | -95.15% | n/a | 78.31M |
| 2022 FY Dec 31, 2021 | $130.58M | $130.58M | -$67.46M | -$44.06M | -$57.33M | 100% | -51.66% | -43.9% | -77.98% | 75.79M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $82.56M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-335103, 0001193125-25-264695 |
| Revenue Growth TTM | -25.17% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-335103, 0001193125-25-264695 |
| Revenue CAGR 3Y | -4.49% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108326 |
| Revenue CAGR 5Y | -9.19% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-108326 |
| Gross Profit CAGR 3Y | 4.72% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108326 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-335103, 0001193125-25-264695 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 50.82% | Gross Profit / Revenue | OK | 0001193125-26-335103, 0001193125-25-264695 |
| Operating Margin | -116.9% | Operating Income / Revenue | OK | 0001193125-26-335103, 0001193125-25-264695 |
| ROIC | -37.13% | NOPAT / Average Invested Capital | OK | 0001193125-26-335103, 0001193125-25-264695 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-335103 |
| Current Ratio | 9.1x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.21 | Revenue / Diluted Shares | OK | 0001193125-26-335103, 0001193125-25-264695 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |